![Cameron Wheeler](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Cameron Wheeler
Director/Board Member at
NUVALENT, INC.
Net worth: 948 250 $ as of 30/05/2026
Profile
Dr. Cameron Wheeler is an Independent Director at Nuvalent, Inc., a Partner at Deerfield Management Co. LP (Private Equity), a Chairman at Civetta Therapeutics LLC and a Chairman at Pairwise Plants Services, Inc. He is on the Board of Directors at Nuvalent, Inc., AlivaMab Biologics LLC, Blade Therapeutics, Inc., Frontier Medicines Corp., Lumos Pharma Sub, Inc., MTrap, Inc., Neomorph, Inc., Ribon Therapeutics, Inc. and Vibliome Therapeutics LLC.
Dr. Wheeler was previously employed as an Independent Director by Homology Medicines, Inc., an Independent Director by Oncorus, Inc., a Manager-Business Development & Operations Team by Constellation Pharmaceuticals, Inc., a Senior Associate by Third Rock Ventures LLC, and a Director-Corporate Development by Eleven Biotherapeutics, Inc. He also served on the board at Graybug Vision, Inc. and Lumos Pharma, Inc. He received his undergraduate degree from Massachusetts Institute of Technology, a graduate degree from Massachusetts Institute of Technology and a doctorate degree from Massachusetts Institute of Technology.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 15/06/2026 | 8,590 ( 0.01% ) | 948 250 $ | 30/05/2026 |
Cameron Wheeler active positions
| Companies | Position | Start |
|---|---|---|
| NUVALENT, INC. | Director/Board Member | 29/03/2022 |
Frontier Medicines Corp.
 Frontier Medicines Corp. Pharmaceuticals: MajorHealth Technology Develops medicines that redefine the course of debilitating diseases | Director/Board Member | - |
Deerfield Management Co. LP (Private Equity)
 Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management invests in both private and public companies located in the United States. The firm targets companies operating in the fields of diagnostic, digital health, life science, medical device, and health care services. It provides financing for pre-seed, seed, early, later and growth stage capital requirements. | Private Equity Investor | 31/08/2014 |
Neomorph, Inc.
 Neomorph, Inc. Pharmaceuticals: MajorHealth Technology Manufactures health drugs | Director/Board Member | - |
Pairwise Plants Services
 Pairwise Plants Services Food: Major DiversifiedConsumer Non-Durables Engages in cultivation of crops | Chairman | - |
AlivaMab Discovery Services LLC
 AlivaMab Discovery Services LLC BiotechnologyHealth Technology Engages in discovery and development of antibody therapeutics | Director/Board Member | - |
Vibliome Therapeutics LLC
 Vibliome Therapeutics LLC Medical SpecialtiesHealth Technology Develops small molecule kinase inhibitors | Director/Board Member | - |
Civetta Therapeutics LLC
 Civetta Therapeutics LLC Pharmaceuticals: MajorHealth Technology Manufactures therapeutics for cancers and other diseases | Chairman | 01/09/2021 |
Blade Therapeutics, Inc.
 Blade Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that focuses on developing treatments for fibrotic and neurodegenerative diseases | Director/Board Member | - |
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Former positions of Cameron Wheeler
| Companies | Position | End |
|---|---|---|
| ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Training of Cameron Wheeler
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
32
1st degree connections
20
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 20 |
|---|---|
Graybug Vision, Inc.
 Graybug Vision, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage biopharmaceutical company, which focuses on developing transformative medicines for the treatment of chronic diseases of retina and optic nerve | Health Technology |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Third Rock Ventures LLC
 Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures invests in companies located in the United States. The firm targets companies operating in the fields of the healthcare sector. It provides financing for early stage capital requirements. It acts as a lead investor. | Finance |
Constellation Pharmaceuticals, Inc.
 Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs targeting regulators of epigenetic function | Health Technology |
Sesen Bio, Inc.
 Sesen Bio, Inc. Pharmaceuticals: MajorHealth Technology Develops protein therapeutics to treat eye diseases | Health Technology |
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Develops and commercializes a novel treatment for the rare disease Creatine Transporter Deficiency | Health Services |
Deerfield Management Co. LP (Private Equity)
Deerfield Management Co. LP (Private Equity) Investment ManagersFinance Deerfield Management invests in both private and public companies located in the United States. The firm targets companies operating in the fields of diagnostic, digital health, life science, medical device, and health care services. It provides financing for pre-seed, seed, early, later and growth stage capital requirements. | Finance |
Blade Therapeutics, Inc.
Blade Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that focuses on developing treatments for fibrotic and neurodegenerative diseases | Health Technology |
Ribon Therapeutics, Inc.
 Ribon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops cacner therapies | Health Technology |
Homology Medicines, Inc.
 Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Operates as clinical-stage genetic medicines company | Health Technology |
Oncorus, Inc.
 Oncorus, Inc. BiotechnologyHealth Technology Operates as biotechnology company that develops next generation immunotherapy platform to treat cancer | Health Technology |
MTrap, Inc.
 MTrap, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in researching and devolving biotechnology | Commercial Services |
Pairwise Plants Services
Pairwise Plants Services Food: Major DiversifiedConsumer Non-Durables Engages in cultivation of crops | Consumer Non-Durables |
Vibliome Therapeutics LLC
Vibliome Therapeutics LLC Medical SpecialtiesHealth Technology Develops small molecule kinase inhibitors | Health Technology |
Frontier Medicines Corp.
Frontier Medicines Corp. Pharmaceuticals: MajorHealth Technology Develops medicines that redefine the course of debilitating diseases | Health Technology |
Civetta Therapeutics LLC
Civetta Therapeutics LLC Pharmaceuticals: MajorHealth Technology Manufactures therapeutics for cancers and other diseases | Health Technology |
Lumos Pharma, Inc.
 Lumos Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and markets therapeutics for rare diseases | Health Technology |
Nuvalent, Inc.
 Nuvalent, Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development and commercialization of targeted therapies for patients with cancer | Health Technology |
AlivaMab Discovery Services LLC
AlivaMab Discovery Services LLC BiotechnologyHealth Technology Engages in discovery and development of antibody therapeutics | Health Technology |
Neomorph, Inc.
Neomorph, Inc. Pharmaceuticals: MajorHealth Technology Manufactures health drugs | Health Technology |
- Stock Market
- Insiders
- Cameron Wheeler
